Trial Profile
A Randomized Sham-controlled Double-masked Phase 2a Study of the Efficacy, Safety and Tolerability of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema Who Have Had Prior Anti-vascular Endothelial Growth Factor Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs KVD 001 (Primary)
- Indications Diabetic macular oedema
- Focus Proof of concept; Therapeutic Use
- Sponsors KalVista Pharmaceuticals
- 09 Dec 2019 Primary endpoint has not been met. (BCVA), according to a KalVista Pharmaceuticals media release.
- 09 Dec 2019 Results presented in a KalVista Pharmaceuticals media release.
- 04 Nov 2019 Status changed from active, no longer recruiting to completed.